Shopping Cart
- Remove All
Your shopping cart is currently empty
EFdA-TP tetrasodium
Catalog No. T72461Cas No. 2883783-00-2
EFdA-TP tetrasodium, a potent nucleoside reverse transcriptase (RT) inhibitor, effectively halts RT-catalyzed DNA synthesis by acting as an immediate or delayed chain terminator (ICT or DCT). It employs multiple mechanisms to inhibit HIV-1 RT [1].
EFdA-TP tetrasodium
Catalog No. T72461Cas No. 2883783-00-2
EFdA-TP tetrasodium, a potent nucleoside reverse transcriptase (RT) inhibitor, effectively halts RT-catalyzed DNA synthesis by acting as an immediate or delayed chain terminator (ICT or DCT). It employs multiple mechanisms to inhibit HIV-1 RT [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,270 | 10-14 weeks | |
| 50 mg | $2,980 | 10-14 weeks | |
| 100 mg | $4,000 | 10-14 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "EFdA-TP tetrasodium"
Emtricitabine
Cited
FTC, Emtriva, BW1592
T6214143491-57-0
Emtricitabine is a nucleoside reverse transcriptase inhibitor with anti-human immunodeficiency virus (HIV) and hepatitis B virus activity, with an EC50 value of 0.01 µM in PBMC cells, and can be used to study HIV infection.
- $45
Size
QTY
CitedLamivudine Cited
GR109714X, BCH-189
T0682134678-17-4
Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
- $53
Size
QTY
CitedStavudine
Sanilvudine, NSC 163661, d4T, BMY-27857
T14043056-17-5
Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV.
ApoptosisAutophagyHIV ProteaseNOD-like Receptor (NLR)Nucleoside Antimetabolite/AnalogReverse Transcriptase
- $33
Size
QTY
Tenofovir Cited
TDF, PMPA, GS 1278
T1649147127-20-6
Tenofovir (GS 1278) is an adenine analog REVERSE TRANSC-RIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
- $37
Size
QTY
CitedTenofovir Disoproxil Fumarate Cited
Tenofovir DF, GS-1278 Disoproxil Fumarate
T2409L202138-50-9
Tenofovir Disoproxil Fumarate (GS-1278 Disoproxil Fumarate) is a pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.
- $46
Size
QTY
CitedTenofovir alafenamide Cited
GS-7340
T2409379270-37-8
Tenofovir alafenamide (GS-7340) is a nucleotide reverse transcriptase inhibitor (NRTI) and a novel ester prodrug of the antiretroviral tenofovir.
- $45
Size
QTY
CitedSalicylanilide
WR10019, 2-Hydroxybenzanilide
T075387-17-2
Salicylanilide (2-Hydroxybenzanilide)s are a group of compounds with antiviral potency, antibacterial and antifungal activities.
- $29
Size
QTY
Methyl gallate Cited
NSC 363001, Gallincin, Gallicin, Gallic acid methyl ester
T373099-24-1
Methyl gallate (Gallincin) is a reverse transcriptase inhibitor with antioxidant, anti-HIV-1 and HIV-1 enzyme inhibition activities.
- $41
Size
QTY
CitedDaidzin Cited
NPI-031D, Daidzoside, Daidzein 7-O-glucoside, Daidzein 7-glucoside
T2901552-66-9
Daidzin (Daidzoside) is an isoflavone isolated from soya bean with anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.
- $37
Size
QTY
CitedOltipraz
RP 35972, NSC 347901
T015364224-21-1
Oltipraz (RP 35972) is a synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H: quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.
- $31
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | EFdA-TP tetrasodium, a potent nucleoside reverse transcriptase (RT) inhibitor, effectively halts RT-catalyzed DNA synthesis by acting as an immediate or delayed chain terminator (ICT or DCT). It employs multiple mechanisms to inhibit HIV-1 RT [1]. |
| In vitro | EFdA-TP tetrasodium, at concentrations ranging from 0.05-10 μM and applied for 15 minutes, acts as a translocation-defective reverse transcriptase (RT) inhibitor, significantly hindering RT-catalyzed DNA synthesis. It operates both as an immediate chain terminator (ICT) and as a delayed chain terminator (DCT), allowing for the insertion of one more deoxynucleotide triphosphate (dNTP) before effectively halting DNA synthesis [1]. |
| Molecular Weight | 621.12 |
| Formula | C12H11FN5Na4O12P3 |
| Cas No. | 2883783-00-2 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy EFdA-TP tetrasodium | purchase EFdA-TP tetrasodium | EFdA-TP tetrasodium cost | order EFdA-TP tetrasodium | EFdA-TP tetrasodium chemical structure | EFdA-TP tetrasodium in vitro | EFdA-TP tetrasodium formula | EFdA-TP tetrasodium molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.